Cargando…
P-159: Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma
Autores principales: | Sgherza, Nicola, Curci, Paola, Rizzi, Rita, Dell’Olio, Grazia, Perfetto, Alberto, Battisti, Olga, Pizzileo, Nicoletta, Strafella, Vanda, De Trizio, Giovanni, Troiano, Teresa, Stefanizzi, Pasquale, Tafuri, Silvio, Musto, Pellegrino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403040/ http://dx.doi.org/10.1016/S2152-2650(22)00489-X |
Ejemplares similares
-
P63 BREAKTHROUGH COVID-19 IN FULL VACCINATED PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE OF 54 PATIENTS
por: Sgherza, N., et al.
Publicado: (2023) -
Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021) -
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study
por: Sgherza, Nicola, et al.
Publicado: (2021) -
COVID-19 in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): An Observational Retrospective Study
por: Sgherza, Nicola, et al.
Publicado: (2021) -
Humoral Immune Response after anti-SARS-CoV-2 Vaccine “Booster” Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)
por: Sgherza, Nicola, et al.
Publicado: (2023)